Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sacubitril-Valsartan Clear all
Terminated Phase 2 Interventional

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT06237309
View directory record Official record
Conditions
Heart Failure
Interventions
REGN5381, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Completed No phase listed Observational

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

NCT04736433
View directory record Official record
Conditions
Heart Failure
Interventions
ACE inhibitor, Sacubitril/Valsartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6,066 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 4, 2026, 1:14 PM EDT
Withdrawn Phase 3 Interventional

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

NCT03508739
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
Interventions
Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 2 Interventional

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

NCT05498181
View directory record Official record
Conditions
Hemodialysis
Interventions
Sacubitril-valsartan, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

NCT04649229
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ 696, Placebo, Para-aminohippurate, Iohexol, Aprepitant
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
LCZ696, Valsartan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 4, 2026, 1:14 PM EDT
Completed No phase listed Observational

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

NCT05096143
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEi/ARB
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
42,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

NCT02884206
View directory record Official record
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 4, 2026, 1:14 PM EDT
Withdrawn Phase 2 Interventional

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184
View directory record Official record
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 4, 2026, 1:14 PM EDT
Terminated Phase 4 Interventional Results available

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

NCT02788656
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Implantable Hemodynamic Monitor, Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

NCT02226120
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Entresto™ 49Mg-51 mg tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 4, 2026, 1:14 PM EDT
Terminated Phase 2 Interventional Results available

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

NCT06142383
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Dothan, Alabama • Huntsville, Alabama • Inverness, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Recruiting Phase 1 Interventional

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

NCT07465653
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
HJB647 low dose, HJB647 high dose, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Bradenton, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 1:14 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

NCT05963282
View directory record Official record
Conditions
de Novo Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 4, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

NCT01876368
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, Placebo of LCZ696, Placebo of Olmesartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Birmingham, Alabama • Fair Oaks, California • Hawaiian Gardens, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 4, 2026, 1:14 PM EDT
Completed No phase listed Observational

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Sacubitril/Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 4, 2026, 1:14 PM EDT
Terminated Phase 4 Interventional Results available

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

NCT03738878
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, LCZ696, Bradykinin, Substance P, BNP, Sitagliptin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 4, 2026, 1:14 PM EDT
Completed No phase listed Observational

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

NCT05613140
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
9,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 4, 2026, 1:14 PM EDT
Not listed No phase listed Observational

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

NCT04743063
View directory record Official record
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 4, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

NCT04055428
View directory record Official record
Conditions
Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
Interventions
Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
Drug · Other · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 4, 2026, 1:14 PM EDT